MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents
Dégradation de protéine ciblée de parp14 pour une utilisation en thérapieInfo
- Publication number
- MA56513A MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
- Authority
- MA
- Morocco
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56513A true MA56513A (fr) | 2022-04-27 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056513A MA56513A (fr) | 2019-06-19 | 2020-06-18 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220388985A1 (fr) |
| EP (1) | EP3986887A1 (fr) |
| JP (2) | JP2022537349A (fr) |
| KR (1) | KR20220024098A (fr) |
| CN (2) | CN114206853A (fr) |
| AU (1) | AU2020296063A1 (fr) |
| BR (1) | BR112021025645A2 (fr) |
| CA (1) | CA3142002A1 (fr) |
| MA (1) | MA56513A (fr) |
| SG (1) | SG11202112980TA (fr) |
| WO (1) | WO2020257416A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230183T1 (hr) | 2017-12-21 | 2023-05-12 | Ribon Therapeutics Inc. | Kinazolinoni kao inhibitori parp14 |
| KR20230144008A (ko) * | 2021-01-08 | 2023-10-13 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 님볼리드 유사체 및 이의 사용 방법 |
| US20220265655A1 (en) * | 2021-01-29 | 2022-08-25 | Ribon Therapeutics, Inc. | Methods of treating inflammatory diseases |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| MA71624A (fr) | 2022-07-29 | 2025-05-30 | Abbvie Operations Singapore Pte. Ltd. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| IL318530A (en) | 2022-07-29 | 2025-03-01 | Abbvie Operations Singapore Pte Ltd | Targeted protein degradation of PARP14 for use in therapy |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (fr) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | Dérivé de quinazolinone et son utilisation médicale |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| KR20240134245A (ko) * | 2014-04-23 | 2024-09-06 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| KR20230127371A (ko) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| JP7227912B2 (ja) * | 2017-02-08 | 2023-02-24 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | キメラ抗原受容体の調節 |
| CA3069181A1 (fr) * | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | Composes pour la degradation de la proteine tau |
-
2020
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/fr not_active Ceased
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/fr active Pending
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/fr active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko active Pending
-
2025
- 2025-04-02 JP JP2025061199A patent/JP2025102917A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020257416A1 (fr) | 2020-12-24 |
| JP2022537349A (ja) | 2022-08-25 |
| AU2020296063A1 (en) | 2021-12-23 |
| BR112021025645A2 (pt) | 2022-02-01 |
| US20220388985A1 (en) | 2022-12-08 |
| JP2025102917A (ja) | 2025-07-08 |
| KR20220024098A (ko) | 2022-03-03 |
| EP3986887A1 (fr) | 2022-04-27 |
| CN120398840A (zh) | 2025-08-01 |
| SG11202112980TA (en) | 2021-12-30 |
| CN114206853A (zh) | 2022-03-18 |
| CA3142002A1 (fr) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| IL289534A (en) | Parp1 inhibitors | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| EA202091865A1 (ru) | Композиции и способы для снижения экспрессии tau | |
| CL2018001724A1 (es) | Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio | |
| EP3847249A4 (fr) | Expression recombinée d'amine oxydase de fumonisine | |
| DK3532059T3 (da) | Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer | |
| DK3737402T5 (da) | Modificeret protein | |
| EP3930852A4 (fr) | Protéines de liaison à l'antigène se liant à bcma | |
| EP3886912A4 (fr) | Dendrimère pour thérapie et imagerie | |
| EP4013440A4 (fr) | Peptides thérapeutiques | |
| EP3972610A4 (fr) | Thérapie à base de mini-gènes | |
| PL4076380T3 (pl) | Przezśluzówkowy system terapeutyczny zawierający agomelatynę | |
| EA201791937A1 (ru) | Противовоспалительные полипептиды | |
| IL280706A (en) | Non-disruptive mitigation of malware attacks | |
| MA71624A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| EP3976100A4 (fr) | Polythérapie | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| MA71618A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| DK3630793T3 (da) | Rekombinant protein | |
| EP3603639A4 (fr) | Agent thérapeutique ou prophylactique pour neuropathies péripheriques | |
| EP3966567A4 (fr) | Peptides thérapeutiques | |
| EP3894546A4 (fr) | Utilisations thérapeutiques de fibroblastes génétiquement modifiés |